Multiple sclerosis is a nightmare disease that has affected a lot of people in the world today, both young and old and it is one that has saddened a lot of individuals as the cure seems to elude patients suffering from this disease.
This is a disease that affects the nervous system of an individual and renders all the tissues useless, making them hard and uncontrollable, ensuring that the carrier gradually loses control of his nervous system and subsequently his movement and speech over time.
However, there is good news as a new stem cell therapy has been discovered to be helping some of the suffering individuals get back to normal.
According to reports from iol, “Medical experts have stated that the treatment – which involves rebooting a patient’s faulty immune system after killing it off with chemotherapy – might even reverse the course of the disease.”
The reports now state that 20 patients have been treated using their own stem cells, and it has yielded incredible results with the patients all resuming their normal lives.
Professor Basil Sharrack, consultant neurologist at the Royal Hallamshire Hospital said about thus development that, “To have a treatment which can potentially reverse disability is really a major achievement.”
According to iol, “The new treatment, known as an autologous haematopoietic stem cell transplant – or HSCT – aims to destroy the faulty immune system using chemotherapy. It then ‘reboots’ it using stem cells harvested earlier from the patient’s own blood.”
Professor John Snowden, consultant haematologist at the Royal Hallamshire Hospital, also said, “The immune system is being reset or rebooted back to a time point before it caused MS. It’s clear we have made a big impact on patients’ lives, which is gratifying.”
The treatment however is said to involve a lot of chemotherapy, so patients are warned before they go in for it of the side-effects of chemo.
Another major snag is that the treatment reportedly costs around £30,000 but since it uses only the individual’s blood, there is little gain for pharmaceutical companies and so there are presently no grants or sponsorship from such companies and it is not sure at this time if this treatment is one that can be sustained over a period of time without the adequate backing.